






Semaglutide is a single-pathway GLP-1, while Tirzepatide targets both GLP-1 and GIP.
Drops are convenient for daily use, while injections usually provide more predictable, long-lasting effects.
GLP-1s are gradual by design. Some patients notice appetite changes sooner with daily Liraglutide, while weekly options like Semaglutide and Tirzepatide often show steady results as treatment continues.
Daily options fit those who prefer routine use, while weekly injections balance convenience with consistency.
No — they also support appetite control and metabolic health as part of broader wellness care.
